SURPASS Clinical Trial Program of Tirzepatide (Mounjaro) in Type 2 Diabetes

Overview of the SURPASS Program

The SURPASS program was a comprehensive phase 3 clinical trial initiative that established tirzepatide as the most potent glucose-lowering and weight-reducing agent available for type 2 diabetes management. 1, 2, 3, 4

The program consisted of five pivotal trials (SURPASS-1 through SURPASS-5) that evaluated tirzepatide across the full spectrum of type 2 diabetes treatment—from monotherapy in newly diagnosed patients through combination therapy with multiple oral agents and insulin. 1, 3, 5

SURPASS-1: Monotherapy Trial

SURPASS-1 was a 40-week, double-blind, placebo-controlled trial that randomized 478 adults with type 2 diabetes inadequately controlled on diet and exercise alone. 1

Key Design Features

Participants had a mean age of 54 years, mean diabetes duration of 4.7 years, and mean BMI of 32 kg/m². 1
The trial compared tirzepatide 5 mg, 10 mg, and 15 mg weekly against placebo. 1
Baseline HbA1c ranged from 7.9% to 8.1% across groups. 1

Efficacy Results

All three tirzepatide doses produced statistically significant HbA1c reductions of -1.6% to -1.8% compared to -0.1% with placebo (treatment difference -1.6% to -1.7%, p<0.001). 1
Between 78% and 85% of tirzepatide-treated patients achieved HbA1c <7% compared to only 23% with placebo. 1
Weight loss ranged from -6.3 kg to -7.8 kg with tirzepatide versus -1.0 kg with placebo (treatment difference -5.3 to -6.8 kg, p<0.001). 1
Fasting glucose decreased by -40 mg/dL with all tirzepatide doses versus +4 mg/dL with placebo. 1

Safety Profile

Only 2-3% of tirzepatide patients required rescue medication compared to 25% with placebo. 1
The trial demonstrated tirzepatide's efficacy as monotherapy without requiring background glucose-lowering medications. 1

SURPASS-2: Head-to-Head Comparison with Semaglutide

SURPASS-2 was a landmark 40-week, open-label trial that directly compared tirzepatide against semaglutide 1 mg (the leading GLP-1 receptor agonist) in 1,879 patients inadequately controlled on metformin alone. 1, 3, 4

Study Population

Mean age was 57 years with 8.6 years of diabetes duration and mean BMI of 34 kg/m². 1
The trial was conducted in a predominantly Hispanic/Latino population (70%). 1

Comparative Efficacy

Tirzepatide 10 mg and 15 mg demonstrated statistically superior HbA1c reduction compared to semaglutide 1 mg, establishing tirzepatide as the most potent glucose-lowering agent available. 1, 3, 4
This head-to-head superiority over semaglutide—previously considered the gold standard GLP-1 RA—was a pivotal finding that distinguished tirzepatide in the diabetes treatment landscape. 2, 3, 4, 6
Weight loss with tirzepatide exceeded that achieved with semaglutide across all doses. 3, 4, 6

Clinical Significance

The trial provided direct evidence that dual GIP/GLP-1 receptor agonism produces greater metabolic benefits than selective GLP-1 receptor activation alone. 3, 4, 5, 6
This comparative data became central to tirzepatide's regulatory approval and clinical positioning. 2, 3

SURPASS-3 and SURPASS-4: Combination Therapy Trials

SURPASS-3 and SURPASS-4 evaluated tirzepatide as add-on therapy to various combinations of oral glucose-lowering medications including metformin, sulfonylureas, and SGLT2 inhibitors. 1, 3, 4

Key Findings Across Combination Trials

Tirzepatide maintained superior efficacy regardless of background therapy, with HbA1c reductions ranging from -1.87% to -2.59% across the dose range. 7, 4, 6
Between 23.0% and 62.4% of patients achieved HbA1c <5.7% (normoglycemia range), an unprecedented outcome for pharmacologic diabetes therapy. 7, 6
Weight loss ranged from 5.4 kg to 12.9 kg depending on dose and background therapy. 4
Tirzepatide demonstrated superiority over insulin degludec and insulin glargine comparators. 1, 2, 3

Cardiometabolic Benefits

Tirzepatide improved multiple cardiovascular risk factors including blood pressure, lipid profiles, and liver fat content across all combination therapy trials. 4, 6
Reductions in new-onset macroalbuminuria suggested potential renal protective effects. 4

SURPASS-5: Insulin Combination Trial

SURPASS-5 specifically evaluated tirzepatide as add-on therapy to basal insulin (with or without metformin), addressing a critical clinical scenario of patients requiring insulin intensification. 1, 3, 4

Clinical Context

This trial targeted patients with more advanced diabetes who had progressed to insulin therapy but remained inadequately controlled. 3, 4
The design reflected real-world practice where many patients eventually require insulin but struggle with weight gain and hypoglycemia. 7

Key Outcomes

Tirzepatide added to basal insulin produced substantial HbA1c reductions while simultaneously reducing body weight—a stark contrast to traditional insulin intensification which typically causes weight gain. 3, 4
The trial demonstrated that tirzepatide could reduce total daily insulin requirements while improving glycemic control. 7, 8
This finding established tirzepatide as a preferred option for insulin intensification over adding prandial insulin, which increases hypoglycemia risk and weight gain. 7

Pooled Safety Analysis Across SURPASS Trials

A comprehensive meta-analysis of cardiovascular events across the entire SURPASS program demonstrated that tirzepatide met cardiovascular safety criteria with no increased risk of major adverse cardiovascular events. 7, 2, 3, 6

Cardiovascular Safety

MACE-4 events (cardiovascular death, non-fatal MI, non-fatal stroke, and hospitalization for angina) showed hazard ratios <1.0 with upper confidence bounds <1.3, fulfilling regulatory cardiovascular safety requirements. 7, 6
Serious adverse events occurred less frequently with tirzepatide compared to insulin (RR 0.79). 7, 9
No increased risk of cardiovascular death was observed across the pooled analysis. 7, 2

Hypoglycemia Risk

Tirzepatide demonstrated a low risk of clinically significant or severe hypoglycemia when used as monotherapy or with metformin. 7, 9, 2
Hypoglycemia risk increased substantially only when tirzepatide was combined with insulin or sulfonylureas, necessitating dose reductions of these agents. 7, 9
The glucose-dependent mechanism of action explains the minimal intrinsic hypoglycemia risk. 7

Gastrointestinal Adverse Events

The most common adverse events were gastrointestinal: nausea (13-22%), diarrhea (12-21%), decreased appetite, and vomiting (6-10%). 9, 2, 4
These events were predominantly mild to moderate in severity, dose-dependent, and typically resolved within 4-8 weeks of reaching each dose level. 7, 4
The safety profile was consistent with that of GLP-1 receptor agonists. 2, 3, 4

Serious Adverse Events

Pancreatitis and gallbladder disease (cholelithiasis, cholecystitis) were reported but causality has not been definitively established. 7
Delayed gastric emptying is a class effect that may persist with chronic tirzepatide use. 7

Unprecedented Efficacy Metrics

The SURPASS program established tirzepatide as having unmatched effectiveness in both glycemic control and body weight reduction compared to all existing diabetes therapies. 2, 3, 4, 6

Glycemic Control

HbA1c reductions of -1.87% to -3.02% across the SURPASS trials represent the most potent glucose-lowering effect of any currently available diabetes medication. 7, 4, 6
The proportion of patients achieving normoglycemia (HbA1c <5.7%) ranged from 23.0% to 62.4%—an outcome previously unattainable with pharmacologic therapy alone. 7, 6
Fasting glucose reductions of -40 to -43 mg/dL were consistently observed. 1

Weight Loss

Body weight reductions ranged from 5.4 kg to 12.9 kg (approximately 6% to 15% of baseline weight) across the SURPASS trials, with higher doses producing greater weight loss. 4, 6
Between 20.7% and 68.4% of patients lost more than 10% of their baseline body weight—a threshold associated with significant cardiometabolic benefits. 6
The magnitude of weight loss with tirzepatide approaches that seen with bariatric surgery, marking a paradigm shift in pharmacologic obesity management. 7

Mechanistic Insights from SURPASS

The SURPASS program provided clinical validation of the dual GIP/GLP-1 receptor agonism concept, demonstrating that combining these incretin pathways produces synergistic metabolic effects. 3, 4, 5, 6

Dual Incretin Mechanism

Tirzepatide's superior efficacy compared to selective GLP-1 agonists (like semaglutide) confirmed that GIP receptor activation provides additive metabolic benefits beyond GLP-1 alone. 3, 4, 5, 6
The mechanism involves enhanced insulin secretion, improved insulin sensitivity, greater glucagon suppression, and more potent appetite reduction than GLP-1 monotherapy. 4, 5, 6
GIP and GLP-1 co-activation produces synergistic effects on insulin response and glucagonostatic response that exceed the sum of their individual effects. 5

Metabolic Improvements

Tirzepatide improved insulin sensitivity and insulin secretory responses to a greater extent than semaglutide. 6
Prandial insulin and glucagon concentrations were lower with tirzepatide compared to semaglutide. 6
Both drugs caused similar reductions in appetite, yet tirzepatide produced greater weight loss, suggesting additional metabolic mechanisms beyond appetite suppression. 6

Regulatory Impact and Approval

The SURPASS program data supported regulatory approval of tirzepatide (Mounjaro) by the FDA (May 13,2022), European Commission (September 25,2022), and regulatory authorities in Japan and other countries. 2, 3

Approval Basis

The five SURPASS trials collectively demonstrated superior efficacy, acceptable safety, and cardiovascular safety across diverse patient populations. 2, 3
Tirzepatide received approval as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1, 2
The approval was based on the totality of evidence showing unprecedented glucose-lowering and weight-reduction efficacy. 2, 3, 4

Clinical Practice Implications

The SURPASS program established tirzepatide as a preferred treatment option across the type 2 diabetes treatment spectrum, from newly diagnosed patients to those requiring insulin intensification. 7, 3, 4

Treatment Positioning

Tirzepatide should be considered as first-line injectable therapy for patients with type 2 diabetes requiring medication beyond metformin, especially those with obesity or overweight. 7
For patients requiring substantial HbA1c reduction (≥1.5% above goal), tirzepatide is the preferred agent due to its superior glucose-lowering potency. 7
When total body weight loss is an important treatment goal, tirzepatide demonstrates superior efficacy compared to all other glucose-lowering medications. 7

Insulin Sparing Effects

Tirzepatide is preferred over insulin in adults with type 2 diabetes without evidence of insulin deficiency, providing greater glycemic effectiveness with beneficial effects on weight and lower hypoglycemia risk. 7
When adding tirzepatide to existing insulin therapy, reduce insulin dose by 20% to minimize hypoglycemia risk. 7

Concomitant Medication Management

Do not use DPP-4 inhibitors concurrently with tirzepatide due to lack of additional glucose lowering beyond tirzepatide alone. 7
Reassess the need for and/or dose of sulfonylureas, meglitinides, and insulin when initiating tirzepatide to minimize hypoglycemia risk. 7

Ongoing Research: SURPASS-CVOT

The cardiovascular outcomes trial (SURPASS-CVOT) is currently evaluating whether tirzepatide reduces major adverse cardiovascular events in patients with type 2 diabetes and established cardiovascular disease or multiple risk factors. 3, 6

Results are expected in 2024 and will determine whether tirzepatide achieves cardiovascular superiority (not just safety) similar to some GLP-1 receptor agonists. 3, 6
Pooled SURPASS data showed favorable trends with MACE-4 hazard ratios <1.0, suggesting potential cardiovascular benefit, but definitive evidence awaits the dedicated outcomes trial. 6

Common Pitfalls to Avoid

Do not delay treatment modification for adults not meeting individualized treatment goals; the SURPASS program demonstrated that early, aggressive therapy produces superior outcomes. 7
Do not combine tirzepatide with DPP-4 inhibitors as this provides no additional glucose lowering. 7
Do not use tirzepatide in pregnant adults as the guideline population specifically excludes pregnancy. 7
Do not overlook the need to reduce insulin and sulfonylurea doses when initiating tirzepatide to prevent hypoglycemia. 7

Summary of SURPASS Program Significance

The SURPASS clinical trial program established tirzepatide as marking a new era in type 2 diabetes management through dual agonism of gut hormones, delivering unmatched glycemic control and weight reduction with an acceptable safety profile. 2, 3, 4, 6

The five pivotal trials demonstrated consistent superiority across diverse patient populations, background therapies, and disease stages—from monotherapy through insulin combination. 1, 2, 3, 4 The program's rigorous design, large patient numbers, and head-to-head comparisons against leading therapies provided the evidence base for tirzepatide's regulatory approval and clinical adoption as a transformative diabetes treatment. 2, 3, 4

Can you summarize the SURPASS clinical trial program of tirzepatide (Mounjaro) in adults with type 2 diabetes?

Help us tailor your experience